Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Influence of the anti-MUC16 humanized monoclonal antibody AR9.6 on gene expression in MUC16 expressing cancer cells in patient-derived organoids

ABSTRACT: Influence of the anti-MUC16 humanized monoclonal antibody AR9.6 on gene expression in MUC16 expressing cancer cells in patient-derived organoids

PROVIDER: PRJNA960655 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24267204_1.fastq.gz	Fastqsanger.gz
	SRR24267204_2.fastq.gz	Fastqsanger.gz
	SRR24267205_1.fastq.gz	Fastqsanger.gz
	SRR24267205_2.fastq.gz	Fastqsanger.gz
	SRR24267206_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Influence of the anti-MUC16 humanized monoclonal antibody AR9.6 on gene expression in MUC16 expressing cancer cells in patient-derived organoids

Project description:To investigate the differentially expressed genes and the pathways they might alter upon humanized AR9.6 mediated blockade of MUC16 and subsequent perturbation of its downstream signaling We then performed gene expression profiling analysis using data obtained from RNA-seq of the two different conditions (organoids treated with huAR9.6 versus huIgG) (three replicates each).

2025-04-30 | GSE230355 | GEO

A humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice

Project description:This study was to test the efficacy of a humanized monoclonal antibody, IC100 for ASC, an apoptosis-associated speck-like protein containing a caspase recruitment domain that is pivotal in inflammasome assembly, in the prevention and treatment of an oxygen-induced retinopathy (OIR) mouse model.

2025-05-01 | GSE261490 | GEO

Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors

Project description:RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of maytansinoid DM4-conjugated humanized monoclonal antibody huC242 in treating patients with solid tumors that cannot be removed by surgery or have spread to other parts of the body.

| 2030868 | ecrin-mdr-crc

A humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice

Project description:A humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice

| PRJNA1087306 | ENA

A Humanized Monoclonal Antibody Targeting an Ectonucleotidase Rescues Heart Function after Myocardial Infarction

Project description:A Humanized Monoclonal Antibody Targeting an Ectonucleotidase Rescues Heart Function after Myocardial Infarction

| PRJNA1076596 | ENA

A Humanized Monoclonal Antibody Targeting an Ectonucleotidase Rescues Heart Function after Myocardial Infarction

Project description:We have recently demonstrated that the ectonucleotidase ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) is upregulated in the heart after myocardial infarction (MI) and initiates an aberrant metabolic cascade that worsens cell death and heart repair. Genetic loss of function approaches demonstrated that animals deficient in ENPP1 exhibited enhanced heart repair and had significantly superior post MI heart function. Whether human ENPP1 protein can be therapeutically targeted after heart injury remains unknown. Here, we engineer a humanized monoclonal antibody targeting human ENPP1 (hENPP1mAb) and demonstrate high affinity and specificity of binding to the catalytic domain of human ENPP1. In mice, genetically engineered, to express the human ENPP1 ortholog instead of murine ENPP1 (humanized ENPP1 mice), we demonstrate that administration of hENPP1mAb significantly rescued post MI heart function compared to IgG injected animals. Using metabolomics, single nuclear transcriptomics, and cellular respiration assays, we demonstrate that administration of the hENPP1mAb induces organ wide metabolic and transcriptional reprogramming of the heart that enhances myocyte cellular respiration and decreases cell death and fibrosis in the infarcted heart. Biodistribution and safety studies with radiolabeled hENPP1mAb showed specific organ wide distribution without any organ toxicity. Finally, in humanized ENPP1 animals that have also been genetically engineered to exhibit antibody clearance kinetics similar to humans, we demonstrate that a single "shot" of the hENPP1mAb after MI is sufficient to rescue post infarct cardiac dysfunction. Taken together our observations provide proof of concept on how the human ectonucleotidase ENPP1 can be therapeutically targeted to prevent heart failure after MI.

2024-10-14 | GSE255826 | GEO

Humanized antibody-drug conjugates for SSTR2-positive tumor treatment

Project description:Somatostatin receptor 2 (SSTR2) is overexpressed in neuroendocrine tumors (NETs) and meningiomas. The objective of this study was to develop an SSTR2-targeted therapy to treat both tumor types. We engineered and humanized an anti-SSTR2 monoclonal antibody (mAb) demonstrating strong cancer cell binding, internalization in cancer cells, and tumor specificity, as evidenced by flow cytometry, confocal microscopy, and live-animal imaging. Antibody-drug conjugates (ADCs) were generated by conjugating the SSTR2 mAb with potent payloads, including monomethyl auristatin F (MMAF) or mertansine (DM1). In vitro assessments revealed high cytotoxicity across diverse NET subtypes and meningioma cell lines. In vivo efficacy was confirmed in two mouse models, i.e. subcutaneous NET xenografts and intracranial meningioma xenografts, where treatment inhibited proliferation, induced apoptosis and cell death, exhibited minimal toxicity, and extended survival. The mechanism of action was further elucidated through bulk RNA sequencing post-treatment. These findings highlight the therapeutic potential of our humanized SSTR2 mAb for targeted payload delivery in NETs and meningiomas.

2025-08-12 | GSE304978 | GEO

Human RP105 monoclonal antibody enables the production of antigen-specific antibody

Project description:Human RP105 monoclonal antibody enables the production of antigen-specific antibody

| PRJNA1006628 | ENA

A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer

Project description:This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in combination with FOLFIRI in patients with previously treated metastatic colorectal cancer. This study includes two stages. Stage 1 is the dose-escalation stage. Once the maximum tolerated dose (MTD) of Sevacizumab has been established, additional patients will be enrolled in the cohort-expansion stage (Stage 2).

| 2190733 | ecrin-mdr-crc

Spatial transcriptomics reveals distinct tumor microenvironment of murine breast cancer model undergoing treatment with a humanized monoclonal antibody targeting FABP4

Project description:Spatial transcriptomics reveals distinct tumor microenvironment of murine breast cancer model undergoing treatment with a humanized monoclonal antibody targeting FABP4

| PRJNA1100989 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data